Showing results (1201-1210 of 2,993) with videos related to
Sort By:
Pageof 300
Seminars in Thrombosis and Hemostasis|January 1, 1997
Synthesis and biological effects of N-alkylamine-labeled low-molecular-mass dermatan sulfateR Malsch, M Guerrini, C Berti, et al.Seminars in Thrombosis and Hemostasis|January 1, 1997
Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparinW Jeske, J Fareed, V Eschenfelder, et al.Seminars in Thrombosis and Hemostasis|January 1, 1997
Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparinJ Harenberg, G Huhle, L Piazolo, et al.Seminars in Thrombosis and Hemostasis|January 1, 1997
Treatment of deep vein thrombosis: is thrombosis regression a desirable endpoint?H K BreddinSeminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndromeB E Lewis, J M Walenga, D E WallisSeminars in Thrombosis and Hemostasis|January 1, 1997
Which glycosaminoglycans are suitable for antithrombogenic or athrombogenic coatings of biomaterials? Part II: Covalently immobilized endothelial cell surface heparan sulfate (ESHS) and heparin (HE) on synthetic polymers and results of animal experimentsH Baumann, R KellerSeminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.Seminars in Thrombosis and Hemostasis|January 1, 1979
Thrombotic thrombocytopenic purpura. An extended editorialR M Nalbandian, R L Henry, R L BickSeminars in Thrombosis and Hemostasis|April 1, 1987
Thrombolytic treatment of acute thrombotic obstruction with disk valve prostheses: experience with 26 casesM F Roudaut, L Ledain, R Roudaut, et al.Pageof 300